Naima Alexander, PA
Physician Assistant · Seaford, NYNPI 1568855591
Payments from drug & device makers
Across 138 payments — averaging $65.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bioprotect LTD.$4K
- Johnson & Johnson$2K
- Progenics Pharmaceuticals, Inc.$362
- Pfizer$321
- Dendreon Pharmaceuticals LLC$240
- Astellas Pharma US Inc$238
- plus $2K from 29 others
Across 1 payment — averaging $4000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bioprotect LTD.$4K
What the payments were for
- Consulting fees$5,00055%
- Travel & lodging$4725%
- Food & beverage$3,36237%
- Education$1972%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bioprotect LTD. | 1 | $4,000 |
| Johnson & Johnson | 24 | $2,175 |
| Progenics Pharmaceuticals, Inc. | 9 | $362 |
| Pfizer | 11 | $321 |
| Dendreon Pharmaceuticals LLC | 10 | $240 |
| Astellas Pharma US Inc | 6 | $238 |
| Antares Pharma, Inc. | 8 | $205 |
| Bayer | 9 | $194 |
| Sumitomo Pharma America, Inc. | 6 | $145 |
| Merck | 6 | $124 |
| Urogen Pharma, Inc. | 4 | $101 |
| Tolmar, Inc. | 5 | $101 |
| Endo Pharmaceuticals Inc. | 5 | $92 |
| AbbVie | 4 | $90 |
| Urovant Sciences Inc | 3 | $75 |
| Tolmar Pharmaceuticals, Inc. | 4 | $65 |
| Acerus Pharmaceuticals Corporation | 4 | $64 |
| Convatec Inc. | 1 | $54 |
| Myriad Genetic Laboratories, Inc. | 1 | $36 |
| Amgen | 2 | $34 |
| Tactile Systems Technology Inc | 1 | $29 |
| Ferring Pharmaceuticals Inc. | 1 | $28 |
| Accord Healthcare, Inc. | 1 | $24 |
| Halozyme Inc | 1 | $24 |
| Novartis | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Sanofi | 1 | $20 |
| Bard Peripheral Vascular, Inc. | 1 | $20 |
| Teleflex LLC | 1 | $19 |
| Blue Earth Diagnostics | 1 | $19 |
| Menarini Silicon Biosystems, Inc. | 1 | $18 |
| Telix Pharmaceuticals | 1 | $18 |
| Verity Pharmaceuticals Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BIOPROTECT BALLOON IMPLANT SYSTEM$4,000
- Erleada$1,443
- PYLARIFY$146
- AKEEGA$125
- XTANDI$122
How this compares
$9,030 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 124 | $82,610 |
| XyostedTestosterone Enanthate | 65 | $45,061 |
| GemtesaVibegron | 44 | $36,521 |
| Methenamine Hippurate | 141 | $12,538 |
| Mirabegron ErMirabegron | 16 | $8,054 |
| Tamsulosin Hcl | 545 | $7,355 |
| Testosterone | 42 | $6,471 |
| Testosterone Cypionate | 64 | $2,907 |
| Solifenacin Succinate | 29 | $2,741 |
| Finasteride | 143 | $2,392 |
| Oxybutynin Chloride ErOxybutynin Chloride | 114 | $2,143 |
| Tadalafil | 16 | $1,944 |
| Tolterodine Tartrate ErTolterodine Tartrate | 20 | $1,534 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 88 | $1,299 |
| Silodosin | 12 | $997 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $238 | $82,610124 claims |
| Antares Pharma, Inc.Xyosted | $205 | $45,06165 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $145 | $36,52144 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.
Other physician assistant in Seaford
- Henry YuBronx$1M
- Michael AsbachAmherst$962K
- Janelle BunceJamestown$565K
- Kristyl Cuenca-SiskoNew York$478K
- Melissa WhiteGarden City$320K
- Lawrence HermanHolbrook$315K
- Kaitlyn NelsonBrooklyn$289K
- Sari KatzGarden City$271K
- Julius NwosuBronx$256K
- Cameron KiserNew York$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.